Understanding processes regulating prostate cancer cell survival is critical to management of advanced disease. We used prostate cancer cell transfectants genetically modified to be deficient in either endogenous fibroblast growth factor (FGF-1) or endogenous FGF-2 to examine FGF maintenance of transfectant survival and proliferation and FGF-2-regulated expression of transfectant growth arrest DNA damage (GADD) and growth arrest sequences (GAS) family genes (known modulators of cell cycle progression and survival) and the AS3 gene (an androgen-modulated effector of prostate cell proliferation). When propagated in the absence of exogenous FGFs, FGF-2-deficient transfectants undergo exponential death, whereas FGF-1-deficient transfectants pro...
Fibroblast growth factor receptors (FGFRs) 1–4 are involved in prostate cancer (PCa) regulation, but...
Fibroblast growth factor receptors (FGFRs) 1–4 are involved in prostate cancer (PCa) regulation, but...
Advanced castrate-resistant prostate cancer (CRPC) is a poorly prognostic disease currently lacking ...
Background: Expression of fibroblast growth factors (FGFs) is increased in a substantial fraction of...
BACKGROUND. Alterations in fibroblast growth factors (FGFs) production and/or FGF receptors expressi...
BACKGROUND: The fibroblast growth factor (FGF) axis is an important mitogenic stimulus in prostate c...
Fibroblast Growth Factors (FGFs) are a family of proteins possessing paracrine, autocrine or endocri...
Fibroblast growth factor receptors (FGFRs) mediate the tumourigenic effects of FGFs in prostate canc...
Fibroblast growth factor (FGF) 2 (or basic FGF) is expressed at increased levels in human prostate c...
Fibroblast growth factor 8 (FGF-8) is expressed at an increased level in a high proportion of prosta...
Metastatic castrate-resistant prostate cancer (CRPC) remains uncurable and novel therapies are neede...
Fibroblast growth factors (FGFs) are potent mitogens, morphogens, and inducers of angiogenesis, and ...
DNA damage found in prostate cancer-associated fibroblasts (CAF) promotes tumor progression. In the ...
Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) play an important role in the maintenance...
Cancer stem cells have been extensively studied in numerous cancers, however, there is no clear iden...
Fibroblast growth factor receptors (FGFRs) 1–4 are involved in prostate cancer (PCa) regulation, but...
Fibroblast growth factor receptors (FGFRs) 1–4 are involved in prostate cancer (PCa) regulation, but...
Advanced castrate-resistant prostate cancer (CRPC) is a poorly prognostic disease currently lacking ...
Background: Expression of fibroblast growth factors (FGFs) is increased in a substantial fraction of...
BACKGROUND. Alterations in fibroblast growth factors (FGFs) production and/or FGF receptors expressi...
BACKGROUND: The fibroblast growth factor (FGF) axis is an important mitogenic stimulus in prostate c...
Fibroblast Growth Factors (FGFs) are a family of proteins possessing paracrine, autocrine or endocri...
Fibroblast growth factor receptors (FGFRs) mediate the tumourigenic effects of FGFs in prostate canc...
Fibroblast growth factor (FGF) 2 (or basic FGF) is expressed at increased levels in human prostate c...
Fibroblast growth factor 8 (FGF-8) is expressed at an increased level in a high proportion of prosta...
Metastatic castrate-resistant prostate cancer (CRPC) remains uncurable and novel therapies are neede...
Fibroblast growth factors (FGFs) are potent mitogens, morphogens, and inducers of angiogenesis, and ...
DNA damage found in prostate cancer-associated fibroblasts (CAF) promotes tumor progression. In the ...
Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) play an important role in the maintenance...
Cancer stem cells have been extensively studied in numerous cancers, however, there is no clear iden...
Fibroblast growth factor receptors (FGFRs) 1–4 are involved in prostate cancer (PCa) regulation, but...
Fibroblast growth factor receptors (FGFRs) 1–4 are involved in prostate cancer (PCa) regulation, but...
Advanced castrate-resistant prostate cancer (CRPC) is a poorly prognostic disease currently lacking ...